anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
The ocular surface comprises the cornea, conjunctiva, eyelids and lacrimal glands and any disorder in these structures can be classified as an ocular surface disorder (OSD). OSD includes Dry Eye Disease (DED), blepharitis and meibomian gland dysfunction (MDG), allergic eye diseases (AED), chemical and thermal burns; all these conditions can severely affect eyesight and quality of life, and sometime even blindness. Patients with OSD can develop photophobia, corneal scarring, intermittent blurred vision, pain, limited ability to perform daily activities, reduced vitality, poor general health and, in many cases, depression.

Glaucoma, one of the leading causes of irreversible blindness, is an optic neuropathy characterized by thinning of retinal nerve fiber layer and increase of optic disc cupping , whose main risk factor is closely related to the intraocular pressure (IOP) levels. Thus, the management of the disease consists in the lowering IOP through medical, laser or surgical therapy . However, IOP reduction is most commonly achieved using topical ocular medications, which often contain preservatives employed to maintain stability and sterility of the product. Preservatives can be associated with undesirable adverse effects such as allergy, local irritation and inflammation . The long-term use of anti-glaucoma medications produces several alterations of ocular surface components, especially at the conjunctival level where epithelial modifications, dendritic cell activation, conjunctiva-associated lymphoid tissue activation, and goblet cell (GCs) loss easily occur GCs play crucial tasks in the homeostasis of the ocular surface being the main source of mucoproteins, essential to maintain tear film stability. Thus, the loss of GCs progressively leads to the happening of an iatrogenic OSD . Moreover, advancing age is a significant risk factor for both OSD and glaucoma, further complicated by treatments for each condition, which can interact among them and yield counterproductive effects . For these reason glaucoma is often associated with OSD .Ocular surface inflammation is crucial in the pathophysiology of OSD, therefore anti-inflammatory therapy, including corticosteroids, may be of benefit to OSD patients . However, in susceptible individuals steroid-induced glaucoma or ocular hypertension can occur after steroid use. Individuals who develop an increase in IOP following steroid use are referred to as "steroid responders" . In a recent study Kallab et al. have found that dry eye treatment with low hydrocortisone dose reduced ocular inﬂammation without inducing increases in IOP ; glaucomatous patients were excluded from this study. Herein we evaluate the safety and efficacy of hydrocortisone eye drops in the treatment of OSD patients with and without glaucoma.
BACKGROUND: Clostridioides difficile infection (CDI) is an increasingly common disease in healthcare facilities and community settings. However, there are limited reports of community-onset CDI (CO-CDI) in China.
METHODS: We collected diarrheal stool samples from 3885 patients who went to outpatient department or emergency department in a tertiary hospital in China during 2010-2023, analyzed the correlation between patients' basic information and the detection rate of CDI. Besides, all stool samples from 3885 outpatients included were tested by culturing. Moreover, we randomly selected 89 patients' stools during the 14 years and isolated 126 C. difficile strains from them. The presence of toxin genes (tcdA, tcdB, cdtA, and cdtB) were confirmed by PCR. Toxigenic strains were typed using multilocus sequence typing (MLST). Susceptibility to 9 antimicrobials was evaluated using the E-test.
RESULTS: 528 of 3885 patients (13.6 %) with diarrhea were finally diagnosed as CDI. The median age of patients included was 51 years (6 months-95 years), while the median of patients with CDI was older than patients with negative results [55.5 years (6 months-93 years) vs. 50 years (9 months -95 years), p < 0.001]. In winter, patients with diarrhea might be more likely to have CDI. The detection rate of CDI of patients in emergency department was much higher than those in other outpatients (20.7 % vs. 12.4 %, p < 0.001), and did differ from each outpatient departments (p < 0.05). There were 95 isolated strains detected as toxigenic C. difficile. Among these strains, 82 (86.3 %) had the tcdA and tcdB genes (A+B+) and 5 of these 82 strains were positive for the binary toxin genes (cdtA and cdtB) (A+B+CDT+). There were 15 different sequence types (STs) by multilocus sequence typing (MLST), while the most ST was ST-54 (23.2 %). ST types composition was relatively stable over the time span of this study. Some strains had high resistance to ciprofloxacin, clindamycin, and erythromycin. Twenty-three isolates (24.2 %) were multidrug-resistant.
CONCLUSIONS: Outpatients with CDI were common among patients having diarrhea during this period in our hospital. Elderly patients and patients went to emergency department may be susceptible to CDI. Based on MLST, the result revealed that the C. difficile isolates had high genetic diversity and maintained stability in this period. All isolates were susceptible to metronidazole and vancomycin, and nearly one quarter of all isolates had multidrug resistance.
E3112 intravenous infusion in treatment stage 1 followed by placebo intravenous infusion in treatment stage 2. A washout period of 7 days will be maintained between the two treatment stages.
Gilteritinib will be taken once daily on study days 1 through 14 and days 16 through 47. On day 15, each participant will be given a single dose of 14C-labeled gilteritinib.
Osteonecrosis of the jaw is a known adverse reaction to antiresorptive medication, including bisphosphonate and denosumab. The globally accepted term is Medication-Related Osteonecrosis of the Jaws (MRONJ). Since 2003 there has been a worldwide focus at medication-related osteonecrosis, even though there still exist several of unanswered questions - one of them is the effect of a drug holiday in relation to tooth extraction. A drug holiday is a temporary discontinuation of a drug and has been suggested among risk reduction strategies in the literature. It is still unknown whether a drug holiday plays a significant role in relation to tooth extraction for the development of osteonecrosis. The investigators want to investigate the importance of an antiresorptive drug holiday (bisphosphonate, denosumab) in relation to tooth extraction.

The aim of this trial is therefore to clarify the meaning of high-dose antiresorptive drug holiday related to tooth extraction with primary mucosal closure in cancer patients and reveal how a drug holiday affects the health related quality of life. A continuation of the patients' antiresorptive treatment can possibly lead to increased risk of osteonecrosis of the jaw, but with the operation procedure with primary closure it is unlikely. It is beneficial for the cancer patients to continue the high dose antiresorptive therapy because a drug holiday is a stop in their anti-cancer treatment with risk of increased pain as well as unwanted skeletal events to occur, and potentially progress of metastases to follow.
A composition comprising ashwagandha root (Withania somnifera), turmeric root (Curcuma longa), lemon balm leaf (Melissa officinalis), Rhodiola rosea root and bilberry fruit (Vaccinium myrtillus). A use of the composition to improve physical and mental health recovery and a use of the composition to prevent cognitive decline are also included. The composition may comprise omega-3, wood betony (Stachys betonica), gingko (Gingko bilboa) or black pepper. The composition may be provided as a powder, capsule, tablet, powdered drink, or liquid, such as a tincture. The composition may be provided in a powdered form to be added to water to form a drink. The composition may be a glycerite, which may comprise glycerine and Tween-80 (RTM, polysorbate-80) in a 4:1 ratio. The solvent of the glycerite may be provided in a 3:1 ratio with the active components. The active components may be in a 1:1:1:1:1 ratio, preferably 1:0.95:1:0.35:0.35. The mass of omega-3 to ashwagandha may be 1:1.4-1.5. The composition may use 1000 mg of ashwagandha root, 950 mg of turmeric root, 1000 mg of lemon balm leaf, 350 mg R. rosea root and 350 mg of bilberry fruit. The composition may include 50 mg of black pepper or 1400-1500 mg omega-3.
PROBLEM TO BE SOLVED: To provide an anti-cancer agent composition, which is excellent in solubility, and has high anti-cancer activity while exhibiting low toxicity.SOLUTION: The anti-cancer agent composition contains a cyclodextrin compound and a phosphine transition metal complex represented by general formula (1). (In the formula, Rand Rrepresent a linear or branched-chain alkyl group, a cycloalkyl group, a cycloalkyl group having a substituent, an adamantyl group, a phenyl group, or a phenyl group having a substituent, have a carbon number between 1 and 10, and may represent the same group or different groups. R3 and R4 represent a hydrogen atom or a linear or branched-chain alkyl group, have a carbon number between 1 and 6, and may represent the same group or different groups. Rand Rmay form a saturated or unsaturated ring by bonding to one another and the saturated or unsaturated ring may have a substituent. M represents a transition metal atom selected from among gold, copper and silver. Xrepresents an anion).
Subjects will be randomized to use the HHHFA device during bedtime for at least 4 hours. Subjects will complete MRC, SGRQ, CAT, CASA-Q and PSQI questionnaires. They will do spirometry, 6-minute walk, and CT scan. These interventions will be done at baseline and at the completion of their study (6 weeks). Spirehealth Device will be worn by subject daily for 12 weeks.
GTV is defined as the intrahepatic lesion on images. Internal target volume (ITV) is defined as the combined volume of GTVs on 10 respiratory phases. Planning target volume (PTV) is generated by adding a 5-mm margin to the ITV. OARs include liver, kidney, stomach, small intestine, and spinal cord. Normal liver volume is defined as the entire liver minus GTV. Dose constraints to OARs were as follows: mean dose of normal liver \< 10 Gy, V15Gy (percentage of the normal liver volume receiving ≥ 15 Gy) \< 35%; kidneys Dmean \< 6 Gy; esophagus D0.5cc \< 21 Gy; stomach D0.5cc \< 21 Gy; small intestine D0.5cc \< 21 Gy; colon D0.5cc \< 24 Gy; heart D0.5cc \< 30 Gy; ribs D0.5cc \< 39 Gy; and spinal cord Dmax \< 18 Gy. SBRT is planned using volumetric arc therapy techniques with a prescription dose of 36-54 Gy in 3 fractions, irradiated every other day, and completed within one week. Cone-beam CT is performed before each treatment.
Non-surgical artificial insemination is achieved for sexed and unsexed equines in a commercially practical manner and with dosages of insemination sperm that were not previously thought to be practical for commercial implementation. Practical and field usable techniques for insemination are presented as well as techniques which offer success ratios at level comparable to the existing routine, high dosage unsexed artificial insemination techniques in equines. Improved insemination and sorting systems particularly adapted to use for sex-selected sperm are disclosed. Such artificial insemination techniques include depositing the sperm at the tip of the uterine horn with a flexible probe or pipette to allow fertilization to occur. Such techniques are further improved by first confirming that the mare has ovulated before insemination. Such techniques allow for the successful insemination with very low numbers of sperm.
The instant invention provides compositions for inhibiting tumor growth or for imaging tumors in a subject and methods of using the same. In one embodiment, the composition comprises transferrin, the anti-tumor agent, and at least one other ligand that selectively binds to tumor cells, or to the endothelial cells of the tumor vasculature. Also provided is a method of inhibiting growth of tumor cells in a mammalian subject, particularly a human subject. The method comprises administering a composition of the present invention to the subject. Also provided is a method of visualizing tumor tissue in a subject. The method comprises administering a composition that comprises radiolabled transferrin operatively linked to a ligand that binds to tumor cells, or a ligand that binds to the endothelial cells of the tumor vasculature, or, preferably a ligand that binds to tumor cells and a ligand that binds to endothelial cells of the tumor vasculature, detecting the radiolabel, and visualizing the tumor tissue.
PURPOSE: A paste composition for ulcer treatment including honey and a manufacturing method thereof are provided to improve properties of cohesive property, transparency, sterilization, and storability. CONSTITUTION: A manufacturing method of paste composition for ulcer treatment comprises the following steps: manufacturing aqueous solution by dissolving biocompatible polymer in purified water(1 step); forming a gel state sheet by pouring aqueous solution into a tray(2 step); irradiating radiation in the aqueous solution(3 step); shattering the gel into pieces(4 step); and manufacturing paste by dissolving pulverized gel, honey, and preservative in the purified water(5 step). The biocompatible polymer is polyvinyl alcohol, polyvinyl pyrrolidone, synthetic high polymer of polyacrylic acid, polyethylene oxide, natural polymer of carrageenan, sodium carboxymethyl cellulose, gelatin, agar, alginate, or chitosan. In step 1, weight ratio of biocompatible polymer mixed in the purified water is 1 to 30 weight%. In step 3, the radiation is gamma-ray, ultraviolet ray, or electronic beam. An amount of the radiant exposure is 2-200 kGy.
PURPOSE: The aim of this study was to compare the accuracy of colonoscopy (CS) and CT colonography (CTC) in the measurement of colorectal polyps using pathological size as a reference.
MATERIALS AND METHODS: The analysis included 61 colorectal polyps in 28 patients who underwent preoperative CTC at our institution. All polyps were endoscopically resected. Polyp sizes were measured by CS and CTC. Endoscopic polyp size was extracted from endoscopy records written by one of two endoscopists (A with 11 and B with 6 years of endoscopic experience, respectively), who estimated the size visually/categorically without any measuring devices. After matching the location, the polyp size was measured on CTC using manual three-dimensional (3D) measurement on a workstation. The sizes of resected polyps were also measured after pathological inspection. Differences of the polyp size between CTC and histology, and between CS and histology were compared using paired t tests. Differences in measurement between the two endoscopists were also analyzed.
RESULTS: The mean diameters of polyps measured using CS, CTC, and pathology were 10.5 mm, 9.2 mm, and 8.4 mm, respectively. There was a significant correlation between CS and pathology, as well as between CTC and pathology (both P < 0.0001). The correlation coefficient for CS (r = 0.86) was lower than that for CTC (r = 0.96). The correlations between CS and pathology for endoscopists A and B were 0.90 and 0.89, respectively.
CONCLUSION: Measurements of polyp size using CTC were closer to the pathological measurements compared to those by CS, which exhibited greater variability. This suggests that CTC may be more suitable for polyp size measurements in the clinical setting if patients undergo CTC concurrently with colonoscopy.
After 3 months, the discharge bundle developed from consensus from the Delphi process will be introduced to both NICUs using Quality Improvement principles. Participants will be recruited after the introduction of the discharge bundle.
In the palatal stimulation group, following the necessary hygiene rules, we used the little finger of one of our hands with a glove on and stimulated the palate and gums of the infants with this finger by slow and peristalsis-like movements for 5 minutes while the infants were fed via OGT. Palatal stimulation group was 30 infants.
Patients in the tight control arm will have additional FiLAC treatment within 24 months if the anatomy of the fistula is favourable. MRI pelvis will be performed at baseline and every 6 months. Biologic dosage will be adjusted according to MRI pelvis findings.
Disclosed are methods for separating, recovering, and purifying tetrahydrocannabinolic acid (THCA) salts from an organic solvent solution comprising a mixture of cannabinoids. The methods comprise solubilizing the mixture of cannabinoids in a selected C5-C7 hydrocarbon solvent, adding thereto a selected amine to thereby precipitate a THCA-amine salt therefrom, dissolving the recovered THCA-amine salt in a selected solvent and then adding thereto a selected antisolvent to thereby recrystallize a purified THCA-amine salt therefrom. The recrystallized THCA-amine salt may be decarboxylated to form a mixture of A9-tetrahydrocannabinol (A9-THC) and amine. The A9-THC amine mixture may be acidified to separate the amine from A9-THC. The recovered A9-THC may be concentrated to produce a highly purified A9-THC. Also disclosed are THCA-amine salts produced with amines selected from groups of diamines, amino alcohols, and tertiary amines.
PURPOSE: To obtain a detergent and foaming composition, comprising a pyrimidine derivative and an amphoteric surfactant in combination and useful for inducing and stimulating the growth of hair or delaying the loss thereof. CONSTITUTION: This composition comprises 1-30wt.% at least one amphoteric surfactant selected from amphoteric carboxyglycinates represented by formula I (R1 is an alkyl, heptyl, nonyl, etc., derived from a copra), amphoteric carboxypropionates represented by formula II [(n) is 1 or 2; X is CH2 CH2 COOH or H; Y is COOH, etc.; R2 is an alkyl, a 7C, a 9C, an 11C or a 13C alkyl, etc., derived from the copra] and salts thereof and 0.05-6wt.% pyrimidine derivative represented by formula III [R3 is a group represented by formula IV (R5 and R6 are each and H, preferably a 1-4C alkyl, etc.); R4 is H, an alkyl, an alkynyl, etc.] and acid addition salts thereof and is obtained by mixing the ingredients with a medium and further suitably compounding a usually used ingredient therewith according to a conventional method.  The composition can be prepared in the form of a lotion, a gel, a cream or an emulsion and is useful for treating alopecia.
This article is the fifth in a series of eight articles that comprise a special issue on Family-Centered Early Intervention (FCEI) for children who are deaf or hard of hearing (DHH) and their families, or FCEI-DHH. The 10 FCEI-DHH Principles are organized conceptually into three sections (a) Foundation Principles, (b) Support Principles, and (c) Structure Principles. Collectively, they describe the essential Principles that guide FCEI for children who are DHH and their families. This article describes the Foundation Principles (Principles 1 and Principle 2). The Foundation Principles emphasize the essential elements of ensuring that families with children who are DHH can access early intervention (EI) and other appropriate supports, as well as highlight the need for provision of EI that is family-centered. Implementation of these FCEI-DHH Principles is intended to improve the lives and the outcomes of children who are DHH and their families around the globe.
Chlorhexidine Gluconate Oral Rinse therapy should be initiated directly following a dental prophylaxis. Patients using Chlorhexidine Gluconate Oral Rinse should be reevaluated and given a thorough prophylaxis at intervals no longer than six months. Recommended use is twice daily oral rinsing for 30 seconds, morning and evening after toothbrushing. Usual dosage is 15 mL of undiluted Chlorhexidine Gluconate Oral Rinse. Patients should be instructed to not rinse with water, or other mouthwashes, brush teeth, or eat immediately after using Chlorhexidine Gluconate Oral Rinse. Chlorhexidine Gluconate Oral Rinse is not intended for ingestion and should be expectorated after rinsing.
PURPOSE:To obtain the subject anti-cancer enhancer showing an excellent anti- cancer enhancement effect using in combination with an anti-cancer agent without a side effect to the living body, having a direct lethal effect to cancer cells and effective with a low dosage by blending an alpha,omega-diol as the active component. CONSTITUTION:An alpha,omega-diol of the formula (n is 6-33) is blended as the active component. Among the above-mentioned active component compounds, ones having integer 12-18 as the n value show especially excellent anti-cancer enhancement effect. As concrete examples of the formula, 1,16-hexadecandiol, 1,20- eicosandiol, etc., are exemplified. For its practical use, a dosage form such as injection or drops is prepared, e.g. by adding a surfactant to a compound of the formula and dispersing the compound using ultrasonic waves. As an oral drug, a capsule, etc., is prepared using the enhancer compound in combination with a binder such as gelatin, a stabilizer such as magnesium stearate and others. In addition, the compounds of the formula are obtained by decomposing a natural material such as a wax.
Postoperative intra-abdominal adhesions represent a significant post-surgical problem. Its complications can cause a considerable clinical and cost burden. Herein, our study aimed to investigate the effect of Everolimus on peritoneal adhesion formation after inducing adhesions in rats. In this experimental study, adhesion bands were induced by intraperitoneal injection of 3 ml of 10% sterile talc solution in 64 male albino rats. The first group served as the control group. The second one received oral Prednisolone (1 mg/kg/day), the third received Everolimus (0.1 mg/kg/day), and group four received both drugs with similar dosages for four consecutive weeks. The formation of adhesion bands was qualitatively graded according to the Nair classification. The rats in the control group had extensive adhesions between the abdominal wall and the organs. Regarding substantial adhesion formation, 50% (8/16) of animals in the control group had substantial adhesions, while this rate in the groups receiving Prednisolone, Everolimus, and combination treatment was 31%, 31%, and 31%, respectively. Also, 68.75% (5/11) of the Prednisolone recipients had insubstantial adhesions, the same as Everolimus recipients, while in the combination group, 66.66% (10/15) rats had insubstantial adhesions. Everolimus demonstrated satisfactory results in reducing the rates of induced peritoneal adhesion in an experimental model, similar to Prednisolone and superior to a combination regime.
The aim of the study is to evaluate the effect of Manual Lymphatic Drainage (MLD) massage in arterial and venous circulation of the upper limb ipsilateral of women submitted after axillary lymphadenectomy breast cancer. Will be evaluated 30 volunteers aged between 40 and 60 years, divided into 2 equal groups, submitted at MLD: Group 1 - volunteers who underwent surgery for breast cancer that have lymphedema, subject to manual lymphatic drainage without upper limb elevation; Group 2 - volunteers who underwent surgery for breast cancer that have lymphedema, subject to manual lymphatic drainage with the upper limb elevation to 30º. Data will be collected by ultrasound Doppler in vein and brachial artery before, after MLD, immediately after, and 30 minutes after therapeutic treatment, with and without elevation of 30°, cross over delimitation, being made a therapy session for therapeutic use with and without elevation, with interval period (washout) for seven days. The order of treatment protocols will be randomized by simple raffle for each volunteer. The data within and between groups will be evaluated by a statistical test t student or ANOVA. Otherwise it will be used Kruskal-Wallis followed test by Dunn. Data processing will be performed by software and fixed the critical level of 5% (p\<0,05).